2026-06-14T03:54:59Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/171362025-04-01T07:34:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Lebret, T author Casas, Ana María author Cavo, M author Woll, P J author Deleplace, C author Kennedy, C author Schoen, P author Jackisch, C author 2016-04-12 Bone metastases in patients with solid tumours (ST) and bone lesions in patients with haematological malignancies (HM) are common. Associated skeletal-related events (SREs) cause severe pain, reduced quality of life and place a burden on health care resources. Bone-targeted agents can reduce the risk of SREs. We evaluated the management of bone metastasis/lesions in five European countries (France, Germany, Italy, Spain and the UK) by an observational chart audit. In total, 881 physicians completed brief questionnaires on 17 193 patients during the observation period, and detailed questionnaires for a further 9303 individuals. Patient cases were weighted according to the probability of inclusion. Although a large proportion of patients with bone metastases/lesions were receiving bisphosphonates, many had their treatment stopped (ST, 19%; HM, 36%) or will never be treated (ST, 18%; HM, 13%). The results were generally similar across the countries, although German patients were more likely to have asymptomatic bone lesions detected during routine imaging. In conclusion, many patients who could benefit from bone-targeted agents do not receive bisphosphonates and many have their treatment stopped when they could benefit from continued treatment. Developing treatment guidelines, educating physicians and increasing the availability of new agents could benefit patients and reduce costs. 10.1111/ecc.12490 1365-2354 European journal of cancer care http://hdl.handle.net/10668/9992 27072626 http://hdl.handle.net/20.500.12105/17136 bisphosphonate bone metastases bone-targeted agent haematological malignancy skeletal-related event solid tumour The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.